scholarly journals Double contrast-enhanced ultrasonography evaluation of preoperative Lauren classification of advanced gastric carcinoma

2011 ◽  
Vol 2 ◽  
pp. 287-293 ◽  
Author(s):  
Pintong Huang ◽  
Shiyan Li ◽  
Wilbert S. Aronow ◽  
Zongmin Wang ◽  
Chandra K. Nair ◽  
...  
Keyword(s):  
Gastric Carcinoma ◽  
Double Contrast ◽  
Lauren Classification ◽  
Advanced Gastric Carcinoma ◽  
Contrast Enhanced ◽  
Contrast Enhanced Ultrasonography ◽  
Laurén Classification

A case of solitary bile duct hamartoma with advanced gastric carcinoma: findings in contrast-enhanced ultrasonography

2013 ◽  
Vol 41 (2) ◽  
pp. 203-207 ◽  
Author(s):  
Manabu Watanabe ◽  
Kazue Shiozawa ◽  
Takashi Ikehara ◽  
Aya Sato ◽  
Daigo Matsui ◽  
...  
Keyword(s):  
Bile Duct ◽  
Gastric Carcinoma ◽  
Advanced Gastric Carcinoma ◽  
Contrast Enhanced ◽  
Bile Duct Hamartoma ◽  
Contrast Enhanced Ultrasonography

scholarly journals Predicting lymph node status in patients with early gastric carcinoma using double contrast-enhanced ultrasonography

2011 ◽  
Vol 3 ◽  
pp. 457-464 ◽  
Author(s):  
Nianyu Xue ◽  
Pintong Huang ◽  
Wilbert S. Aronow ◽  
Zongmin Wang ◽  
Chandra K. Nair ◽  
...  
Keyword(s):  
Lymph Node ◽  
Gastric Carcinoma ◽  
Early Gastric Carcinoma ◽  
Lymph Node Status ◽  
Double Contrast ◽  
Node Status ◽  
Contrast Enhanced ◽  
Contrast Enhanced Ultrasonography

scholarly journals A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer

2020 ◽  
Vol 12 ◽  
pp. 175883592093035 ◽  
Author(s):  
Kunning Wang ◽  
Enxiao Li ◽  
Rita A. Busuttil ◽  
Joseph C. Kong ◽  
Sharon Pattison ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Systemic Chemotherapy ◽  
Meta Analysis ◽  
Sensitivity Analyses ◽  
Diffuse Gastric Cancer ◽  
Lauren Classification ◽  
Significant Difference ◽  
Laurén Classification ◽  
Better Than

Background: The association between the survival or efficacy of chemotherapy and the Lauren subtype of gastric cancer (GC) remains unclear. We aimed to clarify whether patients with different Lauren subtypes have different survival after treatment with systemic chemotherapy: intestinal gastric cancer (IGC) patients survived better than patients with mixed type gastric cancer (MGC) or diffuse gastric cancer (DGC) after treatment with systemic chemotherapy. Patients & methods: Relevant studies for the meta-analysis were identified through searching Pubmed, Embase, Cochrane and Ovid up to March 2020. We also included our own prospectively collected cohort of patients that were followed over a 10-year period. Sub-group and sensitivity analyses were also performed. Results: In our prospective cohort, the overall survival (OS) of IGC patients receiving systemic chemotherapy (chemoIGC) [median OS 5.01 years, interquartile range (IQR) 2.63–6.71] was significantly higher than that of DGC patients receiving the same chemotherapy (chemoDGC) (median OS 1.33 years, IQR 0.78–3.33, p = 0.0001). After adjusting for age, gender and cancer stage, there was a significant difference in OS in patients treated with chemotherapy based on the Lauren classification of GC {hazard ratio (HR) for OS of the IGC versus DGC 0.33, [95% confidence interval (CI), 0.17–0.65; p < 0.001]}. In the IGC patients, the adjusted HR associated with chemotherapy was 0.26 (95% CI, 0.12–0.56; p = 0.001), whereas the association was 0.64 (95% CI, 0.30–1.33; p = 0.23) in the DGC patient group. In our meta-analysis, 33 studies comprising 10,246 patients treated with systemic chemotherapy (chemoIGC n = 4888, chemoDGC n = 5358) met all the selection criteria. While we accounted for much of the heterogeneity in these studies, we found that chemoIGC patients showed significantly improved OS [HR, 0.76 (95% CI, 0.71–0.82); p < 0.00001] when compared with similarly treated chemoDGC patients. Conclusion: Our results support the consideration of Lauren subtype when prescribing systemic chemotherapy for GC, particularly for MGC or DGC, which may not benefit from chemotherapy. Lauren classification should be considered to stratify chemotherapy regimens to GC patients in future clinical trials, with particular relevance to MGC or DGC, which is more difficult to treat with current regimens.

Sign in / Sign up

Export Citation Format

Share Document